Bellicum Pharmaceuticals

BIND Therapeutics

BIND Therapeutics is a clinical-stage biopharmaceutical company that seeks to significantly improve patients' lives and treat disease by developing Accurins, targeted and programmable therapeutics that are designed to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Acquired by Pfizer in 2016.

Select Venture Capital & Financial Partners

ARCH Venture Partners Endeavor Capital Management Flagship Pioneering NanoDimension Polaris Partners RUSNANO